바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.84 No.2
Citation Share

Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2021, v.84 no.2, pp.105-114
https://doi.org/10.4046/trd.2020.0098
Joon Young Choi (Division of Allergy and Pulmonary Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
Ji Wonjun (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea..)
(DepartmentPulmonary and Critical Care Medicine, Asan Medical Center)
Chung Chaeuk (Chungnam National University School of Medicine)
Noh Jae Myoung (Department of Radiation Oncology, Samsung Medical Center)

Oh In-Jae (Chonnam National University)
Yoon Hong In (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)



Choi Joon Young (Division of Pulmonary and Critical Care Medicine, De partment of Internal Medicine)
Jang Seung Hun (Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.)
Public Relation Committee of the Korean Association for Lung Cancer (Public Relation Committee of the Korean Association for Lung Cancer)
Joon, Y. C. , Ji, W. , Chung, C. , Noh, J. M. , Oh, I. , Yoon, H. I. , Choi, J. Y. , Jang, S. H. , & Public, R. C. o. t. K. A. f. L. C. (2021). Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients. Tuberculosis & Respiratory Diseases, 84(2), 105-114, https://doi.org/10.4046/trd.2020.0098
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Complementary and alternative medicine (CAM) has been used frequently, and its use continues to increase in lung cancer patients, despite insufficient scientific of its efficacy. To investigate this situation, we analyzed the current awareness and use of CAM in Korean lung-cancer patients. Methods: This prospective survey–based study was performed at seven medical centers in South Korea between August and October 2019. The survey assessed general patient characteristics and the awareness and use of CAM. We analyzed differences in the clinical parameters of patients aware and not aware of CAM and of CAM non-users and users. Results: Of the 434 patients included in this study, 68.8% responded that they were aware of CAM and 30.9% said they had experienced it. In univariate analysis, the patients aware of CAM were younger with poor performance status, had advanced-stage lung cancer, received more systemic therapy, and received concurrent chemoradiation therapy (CCRT). By multiple logistic regression, younger age, poor performance status, advanced stage, and prior CCRT were identified as independent risk factors for CAM awareness. There were no significant differences in the general characteristics and cancer-associated clinical parameters of CAM non-users and users. Conclusion: Specific clinical parameters were associated with patients’ awareness of CAM, although there were no significantly different characteristics between CAM users and non-users.

keywords
Complementary Therapies, Lung Neoplasms, Awareness, Cross-sectional Studies, Prospective Studies

Reference

1.

1. World Health Organization. WHO fact sheets [Internet]. Geneva: World Health Organization; 2018 [cited 2020 Apr 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.

2.

2. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-50.

3.

3. Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, Ahn JS, et al. Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide Lung Cancer Registry. Tuberc Respir Dis 2019;82:118-25.

4.

4. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis 2016;79:58-69.

5.

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.

6.

6. Calcagni N, Gana K, Quintard B. A systematic review of complementary and alternative medicine in oncology: psychological and physical effects of manipulative and body-based practices. PLoS One 2019;14:e0223564.

7.

7. Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst 2018;110:121-4.

8.

8. Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler KC, Kurschat P, et al. Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients. Eur J Cancer 2017;71:70-9.

9.

9. Li CL, Hsia TC, Li CH, Chen KJ, Yang YH, Yang ST. Adjunctive traditional Chinese medicine improves survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a nationwide, population-based cohort study. Integr Cancer Ther 2019;18:1534735419827079.

10.

10. Shen HS, Wen SH. Effect of early use of Chinese herbal products on mortality rate in patients with lung cancer. J Ethnopharmacol 2018;211:1-8.

11.

11. Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, et al. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One 2018;13:e0203058.

12.

12. Li TM, Yu YH, Tsai FJ, Cheng CF, Wu YC, Ho TJ, et al. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. J Ethnopharmacol 2018;213:92-100.

13.

13. Johnson SB, Park HS, Gross CP, Yu JB. Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol 2018;4:1375-81.

14.

14. Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 2005;16:655-63.

15.

15. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 2012;11:187-203.

16.

16. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;(12):1-23.

17.

17. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat 2019;51:1400-10.

18.

18. Bozza C, Gerratana L, Basile D, Vitale MG, Bartoletti M, Agostinetto E, et al. Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: complementary and alternative medicine in oncology. J Cancer Res Clin Oncol 2018;144:2029-47.

19.

19. Kim SH, Shin DW, Nam YS, Kim SY, Yang HK, Cho BL, et al. Expected and perceived efficacy of complementary and alternative medicine: a comparison views of patients with cancer and oncologists. Complement Ther Med 2016;28:29-36.

20.

20. James PB, Bah AJ. Awareness, use, attitude and perceived need for Complementary and Alternative Medicine (CAM)education among undergraduate pharmacy students in Sierra Leone: a descriptive cross-sectional survey. BMC Complement Altern Med 2014;14:438.

21.

21. Rossanaly Vasram R, Zysman M, Ribeiro Baptista B, Ederle C, Nguyen-Thi PL, Clement-Duchene C, et al. Complementary and alternative medicine use by lung cancer patients. Rev Pneumol Clin 2017;73:172-9.

22.

22. Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF, Yeh CC, et al. Use of Complementary traditional Chinese medicines by adult cancer patients in Taiwan: a nationwide populationbased study. Integr Cancer Ther 2018;17:531-41.

23.

23. Verma V, Simone CB 2nd, Werner-Wasik M. Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lng cancer. Cancers (Basel) 2017;9:120.

24.

24. Traditional, complementary and integrative medicine [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Apr 28]. Available from: https://www.who.int/health-topics/traditionalcomplementary-and-integrative-medicine#tab=tab_1.

25.

25. Ou J, Zhu X, Lu Y, Zhao C, Zhang H, Wang X, et al. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer. Eur J Pharm Sci 2017;109:412-8.

26.

26. Yeo SG. Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: a case report. Exp Ther Med 2015;10:769-72.

27.

27. Klimant E, Wright H, Rubin D, Seely D, Markman M. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr Oncol 2018;25:139-48.

28.

28. Yoon TJ, Yoo YC, Kang TB, Baek YJ, Huh CS, Song SK, et al. Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol 1998;20:163-72.

29.

29. Bradley GW, Clover A. Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment. Thorax 1989;44:1047-8.

30.

30. Garaci E, Pica F, Matteucci C, Gaziano R, D’Agostini C, Miele MT, et al. Historical review on thymosin alpha1 in oncology:preclinical and clinical experiences. Expert Opin Biol Ther 2015;15 Suppl 1:S31-9.

31.

31. Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Thorac Cancer 2011;2:213-20.

32.

32. Bae K, Kim E, Kong JS, Kim J, Park SJ, Jun HJ, et al. Integrative cancer treatment may have a survival benefit in patients with lung cancer: a retrospective cohort study from an integrative cancer center in Korea. Medicine (Baltimore) 2019;98:e16048.

33.

33. Yoo HS, Kim JM, Jo E, Cho CK, Lee SY, Kang HS, et al. Modified Panax ginseng extract regulates autophagy by AMPK signaling in A549 human lung cancer cells. Oncol Rep 2017;37:3287-96.

34.

34. Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, et al. Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep 2017;7:46524.

35.

35. Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. N Engl J Med 1998;339:839-41.

36.

36. Bahall M. Prevalence, patterns, and perceived value of complementary and alternative medicine among cancer patients:a cross-sectional, descriptive study. BMC Complement Altern Med 2017;17:345.

37.

37. Sait KH, Anfinan NM, Eldeek B, Al-Ahmadi J, Al-Attas M, Sait HK, et al. Perception of patients with cancer towards support management services and use of complementary alternative medicine: a single institution hospital-based study in Saudi Arabia. Asian Pac J Cancer Prev 2014;15:2547-54.

38.

38. Wode K, Henriksson R, Sharp L, Stoltenberg A, Hok Nordberg J. Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC Complement Altern Med 2019;19:62.

39.

39. Triphuridet N, Henschke C. Landscape on CT screening for lung cancer in Asia. Lung Cancer (Auckl) 2019;10:107-24.

40.

40. Cheng B, Xiong S, Li C, Liang H, Zhao Y, Li J, et al. An annual review of the remarkable advances in lung cancer clinical research in 2019. J Thorac Dis 2020;12:1056-69.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy